基于MRI增强的体素减影技术对复发胶质母细胞瘤患者预后评估的价值

桑紫钒; 康厚艺; 郭虹; 冉启胜; 刘嘉晨; 张伟国

doi:10.16016/j.2097-0927.202308015

您当前的位置：

首页 >

文章列表页 >

基于MRI增强的体素减影技术对复发胶质母细胞瘤患者预后评估的价值

神经科学 | 更新时间：2026-01-09

- 基于MRI增强的体素减影技术对复发胶质母细胞瘤患者预后评估的价值
- Value of MRI enhanced voxel subtraction technique in prognostic assessment for recurrent glioblastoma
- 陆军军医大学学报 2023年45卷第21期页码：2244-2251
- 作者机构：
  
  400042 重庆，陆军特色医学中心放射科，重庆市影像医学与核医学临床研究中心
- 作者简介：
  
  [张伟国，E-mail: wgzhang01@163.com ZHANG Weiguo, E-mail: wgzhang01@163.com
- 基金信息：
  
  国家自然科学基金面上项目(81871421);重庆市临床重点专科建设项目(425Z41)
- DOI：10.16016/j.2097-0927.202308015
  中图分类号： R445.2;R730.7;R739.41
- 收稿：2023-08-03，
  
  修回：2023-10-14，
  
  纸质出版：2023-11-15
- 稿件说明：
移动端阅览
桑紫钒, 康厚艺, 郭虹, 等. 基于MRI增强的体素减影技术对复发胶质母细胞瘤患者预后评估的价值[J]. 陆军军医大学学报, 2023,45(21):2244-2251.

Zifan SANG, Houyi KANG, Hong GUO, et al. Value of MRI enhanced voxel subtraction technique in prognostic assessment for recurrent glioblastoma[J]. Journal of Army Medical University, 2023, 45(21): 2244-2251.
桑紫钒, 康厚艺, 郭虹, 等. 基于MRI增强的体素减影技术对复发胶质母细胞瘤患者预后评估的价值[J]. 陆军军医大学学报, 2023,45(21):2244-2251. DOI： 10.16016/j.2097-0927.202308015.

Zifan SANG, Houyi KANG, Hong GUO, et al. Value of MRI enhanced voxel subtraction technique in prognostic assessment for recurrent glioblastoma[J]. Journal of Army Medical University, 2023, 45(21): 2244-2251. DOI： 10.16016/j.2097-0927.202308015.

摘要

目的

探讨复发性胶质母细胞瘤(recurrent glioblastoma，rGBM)二线治疗前的肿瘤增强体积(V)、总体积(Vn)以及相对非增强体积比(relative non-enhancing tumor ratio，rNTR)对总生存时间(overall survival，OS)以及复发后生存期(post-recurrence survival，PRS)的影响。

方法

回顾性分析2012年7月至2022年12月确诊和治疗的85例rGBM患者。T1加权成像(T1-weighted imaging，T1WI)减影模式下定量测量V、Vn(含肿瘤强化、肿瘤坏死和囊变体积)以及rNTR(FLAIR高信号体积/增强体积)。以Kaplan-Meier生存曲线和log-rank检验分析各指标的高、低水平组间预后差异；采用Cox比例风险回归模型进行单因素、多因素预后分析。

结果

患者中位PRS为238 d(95%

：197.472~278.528)，中位OS为449 d (95%

：348.755~549.245)。Kaplan-Meier曲线和log-rank检验显示V、Vn和rNTR高、低水平组间PRS和OS差异有统计学意义(

均

0.05)。单因素分析中，V、Vn及rNTR均是PRS、OS

的影响因素(

0.05)。多因素分析中，V、Vn是PRS的独立危险因素(

=1.019，

0.001)，Vn是OS的独立危险因素(

=1.008，

=0.042)，Vn-PRS模型在所有模型中-2倍对数似然值(-2 log likelihood，-2LL)最小。

结论

体素减影技术能准确地评估rGBM患者复发肿瘤大小，V、Vn及rNTR可用于预测预后，其中Vn对于PRS的预测效能最佳，能为临床对病变范围和患者生存时间的评估提供可靠的参考依据。

Abstract

Objective

To investigate the values of enhancing tumor volume (V)

total volume (Vn) and relative non-enhancing tumor ratio (rNTR) before second-line treatment on overall survival (OS) and post-recurrence survival (PRS) in recurrent glioblastoma (rGBM).

Methods

Clinical data of 85 patients with confirmed rGBM admitted in our medical center from July 2012 to December 2022 were collected and retrospectively analyzed. Quantitative measurements of V

Vn (including tumor enhancement

necrotic and cystic volume) and rNTR (FLAIR high signal volume/enhancing tumor volume) were performed with T1-weighted imaging (T1WI) subtraction mode. Kaplan-Meier survival curve and log-rank test were used to analyze the differences of prognosis between high and low level groups of above indicators. Cox proportional risk regression model was employed for univariate and multivariate prognostic analyses.

Results

The median PRS was 238 d (95%

: 197.472~278.528) and the median OS was 449 d (95%

: 348.755~549.245) in these patients. Kaplan-Meier curve and log-rank test showed significant differences in PRS and OS between high and low levels groups of V

Vn and rNTR (

0.05). Univariate analysis showed that V

Vn and rNTR were all influencing factors for PRS and OS (

0.05). Multivariate analysis indicated that V and Vn were independent risk factors for PRS (

=1.019

0.001)

and Vn was an independent ris

k factor for OS (

=1.008

=0.042). The Vn-PRS model had the lowest -2 log likelihood (-2LL) among all the models.

Conclusion

Voxel subtraction technique can accurately assess the size of recurrent tumors in rGBM patients. V

Vn and rNTR can be used for prognosis

and Vn is the most valuable predictor for PRS

which can provide a reliable reference for clinical evaluation of the extent of lesions and survival time of patients.

关键词

Keywords

references

WELLER M, VAN DEN BENT M, TONN J C, et al . European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas[J ] . Lancet Oncol, 2017, 18(6): e315-e329. DOI: 10.1016/S1470-2045(17)30194-8.

REARDON D A, BRANDES A A, OMURO A, et al . Effect of nivolumab vs bevacizumab in patients with recurrent glioblastoma: the CheckMate 143 phase 3 randomized clinical trial[J ] . JAMA Oncol, 2020, 6(7): 1003-1010. DOI: 10.1001/jamaoncol.2020.1024.

HENKER C, KRIESEN T, GLASS Ä, et al . Volumetric quantification of glioblastoma: experiences with different measurement techniques and impact on survival[J ] . J Neurooncol, 2017, 135(2): 391-402. DOI: 10.1007/s11060-017-2587-5.

CHELLIAH S S, PAUL E A L, KAMARUDIN M N A, et al . Challenges and perspectives of standard therapy and drug development in high-grade gliomas[J ] . Molecules, 2021, 26(4): 1169. DOI: 10.3390/molecules26041169.

HENKER C, HIEPEL M C, KRIESEN T, et al . Volumetric assessment of glioblastoma and its predictive value for survival[J ] . Acta Neurochir (Wien), 2019, 161(8): 1723-1732. DOI: 10.1007/s00701-019-03966-6.

BENZAKOUN J, ROBERT C, LEGRAND L, et al . Anatomical and functional MR imaging to define tumoral boundaries and characterize lesions in neuro-oncology[J ] . Cancer Radiother, 2020, 24(5): 453-462. DOI: 10.1016/j.canrad.2020.03.005.

ELLINGSON B M, WEN P Y, CLOUGHESY T F. Modified criteria for radiographic response assessment in glioblastoma clinical trials[J]. Neurotherapeutics, 2017, 14(2): 307-320. DOI: 10.1007/s13311-016-0507-6.

SAUER S T, CHRISTNER S A, SCHLAIẞ T, et al . Diffusion-weighted breast MRI at 3 tesla: improved lesion visibility and image quality with a combination of water-excitation and spectral fat saturation[J ] . Acad Radiol, 2023, 30(9): 1773-1783. DOI: 10.1016/j.acra.2023.01.014.

ELLINGSON B M, BENDSZUS M, BOXERMAN J, et al . Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials[J ] . Neuro Oncol, 2015, 17(9): 1188-1198. DOI: 10.1093/neuonc/nov095.

ELLINGSON B M, KIM H J, WOODWORTH D C, et al . Recurrent glioblastoma treated with bevacizumab: contrast-enhanced T1-weighted subtraction maps improve tumor delineation and aid prediction of survival in a multicenter clinical trial[J ] . Radiology, 2014, 271(1): 200-210. DOI: 10.1148/radiol.13131305.

ELLINGSON B M, HARRIS R J, WOODWORTH D C, et al . Baseline pretreatment contrast enhancing tumor volume including central necrosis is a prognostic factor in recurrent glioblastoma: evidence from single and multicenter trials[J ] . Neuro Oncol, 2017, 19(1): 89-98. DOI: 10.1093/neuonc/now187.

ELLINGSON B M, AFTAB D T, SCHWAB G M, et al . Volumetric response quantified using T1 subtraction predicts long-term survival benefit from cabozantinib monotherapy in recurrent glioblastoma[J ] . Neuro Oncol, 2018, 20(10): 1411-1418. DOI: 10.1093/neuonc/noy054.

SOLLMANN N, GUTBROD-FERNANDEZ M, BURIAN E, et al . Subtraction maps derived from longitudinal magnetic resonance imaging in patients with glioma facilitate early detection of tumor progression[J ] . Cancers (Basel), 2020, 12(11): 3111. DOI: 10.3390/cancers12113111.

PATEL K S, EVERSON R G, YAO J W, et al . Diffusion magnetic resonance imaging phenotypes predict overall survival benefit from bevacizumab or surgery in recurrent glioblastoma with large tumor burden[J ] . Neurosurgery, 2020, 87(5): 931-938. DOI: 10.1093/neuros/nyaa135.

LAUKAMP K R, SHAKIRIN G, BAEẞLER B, et al . Accuracy of radiomics-based feature analysis on multiparametric magnetic resonance images for noninvasive meningioma grading[J ] . World Neurosurg, 2019, 132: e366-e390. DOI: 10.1016/j.wneu.2019.08.148.

PARK G E, KIM S H, LEE E B, et al . Ipsilateral recurrence of DCIS in relation to radiomics features on contrast enhance d breast MRI[J ] . Tomography, 2022, 8(2): 596-606. DOI: 10.3390/tomography8020049.

ELLINGSON B M, KIM E, WOODWORTH D C, et al . Diffusion MRI quality control and functional diffusion map results in ACRIN 6677/RTOG 0625: a multicenter, randomized, phase Ⅱ trial of bevacizumab and chemotherapy in recurrent glioblastoma[J ] . Int J Oncol, 2015, 46(5): 1883-1892. DOI: 10.3892/ijo.2015.2891.

ELLINGSON B M, HAGIWARA A, MORRIS C J, et al . Depth of radiographic response (DpR) and time to tumor regrowth (TTG) predicts overall survival following anti-VEGF therapy in recurrent glioblastoma[J ] . Clin Cancer Res, 2023: CCR-C23-1235. DOI: 10.1158/1078-0432.CCR-23-1235.

HE W S, EDNEY M K, PAINE S M L, et al . Untargeted metabolomic characterization of glioblastoma intra-tumor heterogeneity using OrbiSIMS[J ] . Anal Chem, 2023, 95(14): 5994-6001. DOI: 10.1021/acs.analchem.2c05807.

STADLBAUER A, KINFE T M, EYÜPOGLU I, et al . Tissue hypoxia and alterations in microvascular architecture predict glioblastoma recurrence in humans[J ] . Clin Cancer Res, 2021, 27(6): 1641-1649. DOI: 10.1158/1078-0432.CCR-20-3580.

BABACIC H, GALARDI S, UMER H M, et al . Glioblastoma stem cells express non-canonical proteins and exclusive mesenchymal-like or non-mesenchymal-like protein signatures[J ] . Mol Oncol, 2023, 17(2): 238-260. DOI: 10.1002/1878-0261.13355.

HUANG S L, MICHALEK J E, REARDON D A, et al . Assessment of tumor hypoxia and perfusion in recurrent glioblastoma following bevacizumab failure using MRI and 18 F-FMISO PET[J ] . Sci Rep, 2021, 11(1): 7632. DOI: 10.1038/s41598-021-84331-5..

BISEROVA K, JAKOVLEVS A, ULJANOVS R, et al . Cancer stem cells: significance in origin, pathogenesis and treatment of glioblastoma[J ] . Cells, 2021, 10(3): 621. DOI: 10.3390/cells10030621.

SOLAR P, HENDRYCH M, BARAK M, et al . Blood-brain barrier alterations and edema formation in different brain mass lesions[J ] . Front Cell Neurosci, 2022, 16: 922181. DOI: 10.3389/fncel.2022.922181.

TU Z W, WANG C, HU Q, et al . Protein disulfide-isomerase A4 confers glioblastoma angiogenesis promotion capacity and resistance to anti-angiogenic therapy[J ] . J Exp Clin Cancer Res, 2023, 42(1): 77. DOI: 10.1186/s13046-023-02640-1.

FAZZARI F G T, ROSE F, PAULS M, et al . The Current landscape of systemic therapy for recurrent glioblastoma: a systematic review of randomized-controlled trials[J ] . Crit Rev Oncol Hematol, 2022, 169: 103540. DOI: 10.1016/j.critrevonc.2021.103540.

JIANG T, NAM D H, RAM Z, et al . Clinical practice guidelines for the management of adult diffuse gliomas[J ] . Cancer Lett, 2021, 499: 60-72. DOI: 10.1016/j.canlet.2020.10.050.

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

基于磁共振DSC-PWI构建的肿瘤血管生境对胶质母细胞瘤和单发脑转移瘤鉴别诊断效能的研究

多模态MRI评价胶质母细胞瘤中组织因子表达水平的价值

瘤周2 cm水肿带ADC灰度直方图对胶质母细胞瘤空间复发模式的预测价值

T1rho磁共振技术定量评估腰痛患者椎间盘早期退行性改变

基于多转录组测序的胶质母细胞瘤间质样肿瘤亚群缺氧特征及预后研究